Intrathecal/Intracerebroventricular enzyme replacement therapy for the mucopolysaccharidoses: efficacy, safety, and prospects

References

• Neufeld MJ. The mucopolysaccharidoses. In: Scriver CRBA, Sly WS, Valle D, et al., eds. The metabolic and molecular basis of inherited disease. 8 ed. New York, NY: McGraw-Hill; 2001. p. 3421–3452.
   Google Scholar
• Mayer FQ, Pereira Fdos S, Fensom AH, et al. New GLB1 mutation in siblings with Morquio type B disease presenting with mental regression. Mol Genet Metab. 2009;96(3):148.
   PubMed Web of Science ®Google Scholar
• Imundo L, Leduc CA, Guha S, et al. A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis. J Inherit Metab Dis. 2011;34(5):1013–1022.
   PubMed Web of Science ®Google Scholar
• Triggs-Raine B, Salo TJ, Zhang H, et al. Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci U S A. 1999;96(11):6296–6300.
   PubMed Web of Science ®Google Scholar
• Orchard PJ, Milla C, Braunlin E, et al. Pre-transplant risk factors affecting outcome in Hurler syndrome. Bone Marrow Transplant. 2010;45(7):1239–1246.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Whitley CB, Wang RY, et al. A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. Mol Genet Metab. 2018;123(4):488–494.
   PubMed Web of Science ®Google Scholar
• Giugliani R, Federhen A, Vairo F, et al. Emerging drugs for the treatment of mucopolysaccharidoses. Expert Opin Emerg Drugs. 2016;21(1):9–26.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Boado RJ, Giugliani R, et al. Plasma pharmacokinetics of valanafusp alpha, a human insulin receptor antibody-iduronidase fusion protein, in patients with mucopolysaccharidosis type I. Bio Drugs. 2018;32:169–176.
   Google Scholar
• Sonoda H, Morimoto H, Yoden E, et al. A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol Ther. 2018;26(5):1366–1374.
   PubMed Web of Science ®Google Scholar
• De Duve C. From cytases to lysosomes. Fed Proc. 1964;23:1045–1049.
   PubMedGoogle Scholar
• Mapes CA, Anderson RL, Sweeley CC, et al. Enzyme replacement in Fabry’s disease, an inborn error of metabolism. Science. 1970;169(3949):987–989.
   PubMed Web of Science ®Google Scholar
• Brady RO, Tallman JF, Johnson WG, et al. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry’s disease. N Engl J Med. 1973;289(1):9–14.
   PubMed Web of Science ®Google Scholar
• Brady RO, Pentchev PG, Gal AE, et al. Replacement therapy for inherited enzyme deficiency: use of Purified Glucocerebrosidase in Gaucher’s Disease. N Engl J Med. 1974;291(19):989–993.
   PubMed Web of Science ®Google Scholar
• Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991;324(21):1464–1470.
   PubMed Web of Science ®Google Scholar
• Zimran A, Elstein D, Levy-Lahad E, et al. Replacement therapy with imiglucerase for type 1 Gaucher’s disease. Lancet Lond Engl. 1995;345(8963):1479–1480.
   PubMed Web of Science ®Google Scholar
• Hollak CEM, De Sonnaville ESV, Cassiman D, et al. Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients. Mol Genet Metab. 2012;107(3):526–533.
   PubMed Web of Science ®Google Scholar
• Shirley M. Sebelipase Alfa: first Global Approval. Drugs. 2015;75(16):1935–1940.
   PubMed Web of Science ®Google Scholar
• Voelker R. Treatment for rare enzyme disorder. JAMA. 2018;319(1):14.
   Web of Science ®Google Scholar
• Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581–588.
   PubMed Web of Science ®Google Scholar
• Tomanin R, Zanetti A, D’Avanzo F, et al. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years. Orphanet J Rare Dis. 2014;9:129.
   PubMed Web of Science ®Google Scholar
• Parini R, Rigoldi M, Tedesco L, et al. Enzymatic replacement therapy for Hunter disease: up to 9years experience with 17 patients. Mol Genet Metab Rep. 2015;3:65–74.
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Sawamoto K, Shimada T, et al. Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations. Expert Opin Orphan Drugs. 2015;3(11):1279–1290.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144(5):574–580.
   PubMed Web of Science ®Google Scholar
• Harbaugh RE, Saunders RL, Reedert RF. Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery. 1988;23:693–698.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol. 2010;22(6):627–635.
   PubMed Web of Science ®Google Scholar
• Berg S, Nand S. Neurological complications of the leukemias across the ages. Curr Neurol Neurosci Rep. 2017;17(2):13.
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161.
   PubMed Web of Science ®Google Scholar
• Rieselbach RE, Di Chiro G, Freireich EJ, et al. Subarachnoid distribution of drugs after lumbar injection. N Engl J Med. 1962;267:1273–1278.
   PubMed Web of Science ®Google Scholar
• Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987;5:1655.
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Van Horn A, Fisher R, et al. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010;116:1947–1952.
   PubMed Web of Science ®Google Scholar
• Salamat-Miller N, Taylor K, Campolieto P, et al. Methods and compositions for CNS delivery of arylsulfatase A. U.S. Patent No. 9,770,410 (2017)
   Google Scholar
• Obbens EA, Leavens ME, Beal JW, et al. Ommaya reservoirs in 387 cancer patients: a 15-year experience. Neurology. 1985;35(9):1274–1278.
   PubMed Web of Science ®Google Scholar
• Lemann W, Wiley RG, Posner JB. Leukoencephalopathy complicating intraventricular catheters: clinical, radiographic and pathologic study of 10 cases. J Neurooncol. 1988;6(1):67–74.
   PubMed Web of Science ®Google Scholar
• Bleyer WA, Pizzo PA, Spence AM, et al. The Ommaya reservoir: newly recognized complications and recommendations for insertion and use. Cancer. 1978;41(6):2431–2437.
   PubMed Web of Science ®Google Scholar
• Upadhyay SP, Mallick PN. Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates. Am J Hosp Palliat Care. 2012;29:388–398.
   PubMed Web of Science ®Google Scholar
• Bottros MM, Christo PJ. Current perspectives on intrathecal drug delivery. J Pain Res. 2014;7:615–626.
   PubMed Web of Science ®Google Scholar
• Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab. 2007;91(1):61–68.
   PubMed Web of Science ®Google Scholar
• Kakkis E, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab. 2004;83(1–2):163–174.
   PubMed Web of Science ®Google Scholar
• Munoz-Rojas MV, Vieira T, Costa R, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A. 2008;146A(19):2538–2544.
   PubMed Web of Science ®Google Scholar
• Dickson PI, Hanson S, McEntee MF, et al. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. Mol Genet Metab. 2010;101(2–3):115–122.
   PubMed Web of Science ®Google Scholar
• Chen A, Vogler C, McEntee M, et al. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase. APMIS. 2011;119(8):513–521.
   PubMed Web of Science ®Google Scholar
• Dickson PI, Ellinwood NM, Brown JR, et al. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I. Mol Genet Metab. 2012;106(1):68–72.
   PubMed Web of Science ®Google Scholar
• Vera M, Le S, Kan SH, et al. Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis Ipatients. Pediatr Res. 2013;74(6):712–720.
   PubMed Web of Science ®Google Scholar
• Dickson PI, Kaitila I, Harmatz P, et al. Mucopolysaccharidosis I Intrathecal Research Collaborative. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I. Mol Genet Metab. 2015;116(1–2):69–74.
   PubMedGoogle Scholar
• Nestrasil I, Shapiro E, Svatkova A, et al. Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I. Am J Med Genet A. 2017;173(3):780–783.
   PubMed Web of Science ®Google Scholar
• Parini R, Jones SA, Harmatz PR, et al. The natural history of growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2016;117(4):438–446.
   PubMed Web of Science ®Google Scholar
• Lin HY, Chuang CK, Huang YH, et al. Causes of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995-2012. Orphanet J Rare Dis. 2016;11(1):85.
   PubMedGoogle Scholar
• Muenzer J, Hendriksz CJ, Fan Z, et al. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med. 2016;18(1):73–81.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Hendriksz CJ, Stein MB, et al. A long-term extension study evaluating intrathecal idursulfase-IT in children with Hunter syndrome and cognitive impairment. Mol Genet Metab. 2016;120(1):S99–S100.
   Web of Science ®Google Scholar
• Wijburg FA, Wezgrzyn G, Burton BK, et al. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Pæd. 2013;102:462–470.
   PubMed Web of Science ®Google Scholar
• Jones AA, Breen CHF, Rust S, et al. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab. 2016;118:198–205.
   PubMed Web of Science ®Google Scholar
• Shire. Safety, tolerability, ascending dose and dose frequency study of rhHNS Via an IDDD in MPS IIIA patients. In: ClinicalTrialsgov [Internet]. [cited 2018 March 20]. Available from: http://clinicaltrials.gov/show/NCT01155778. NLM identifier: NCT01155778
   Google Scholar
• Shire. Randomized, controlled, open-label, multicenter, safety and efficacy study of rhhns administration via an IDDD in pediatric patients with early stage MPS IIIA disease. In: ClinicalTrialsgov [Internet]. [cited 2018 March 20]. Available from: http://clinicaltrials.gov/show/NCT02060526. NLM identifier: NCT02060526
   Google Scholar
• Biomarin. A treatment study of mucopolysaccharidosis type IIIB (MPS IIIB). In: ClinicalTrialsgov [Internet]. [cited 2018 March 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02754076. NLM identifier: NCT02754076.53
   Google Scholar
• Biomarin. A phase 1/2 open-label dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of intracerebroventricular BMN 250 in patients with mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo Syndrome Type B). In: European Union Clinical Trials Register [Internet]. [cited 2018 March 20]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001985-25/ES. EudraCT Number: 2015-001985-25
   Google Scholar
• Muñoz-Rojas MV, Horovitz DDG, Jardim LB, et al. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis vervicalis. Mol Genet Metab. 2010;99:346–350.
   PubMed Web of Science ®Google Scholar
• [cited 2018 March 20]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search [Last accessed 20 March 2018]
   Google Scholar
• [cited 2018 March 20]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Nestrasil I, Shapiro E, Svatkova A, et al. Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I. Am J Med Genet A. 2017;173(3):780–783.
   PubMed Web of Science ®Google Scholar
• Kiely BT, Kohler JL, Coletti HY, et al. Early disease progression of Hurler syndrome. Orphanet J Rare Dis. 2017;12(1):32.
   PubMedGoogle Scholar
• Barth AL, De Magalhaes T, Reis ABR, et al. Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: a 7 years follow-up. Mol Genet Metab Rep. 2017;12:62–68.
   PubMed Web of Science ®Google Scholar
• Kuiper GA, Meijer OLM, Langereis EJ, et al. Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications. Orphanet J Rare Dis. 2018;13(1):2.
   PubMedGoogle Scholar